Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Sep 18.

Published in final edited form as: Bone Marrow Transplant. 2015 May 11;50(9):1173–1179. doi: 10.1038/bmt.2015.103

Probability of a) relapse b) event free (EFS) and c) overall survival (OS) in ALL patients from all risk categories who had pre-HCT flow MRD measured and lived to day +55 after transplant (n=105). Patients listed as MRD+ had ≥ 0.1% measured by flow cytometry in BM within 2 weeks initiating their preparative regimen. Patients listed as experiencing aGVHD had onset of any grade of aGVHD before day +55. MRD <0.1% and no aGVHD n=51, MRD <0.1% and yes aGVHD n=37, MRD ≥0.1% and no aGVHD n=12, MRD ≥0.1% and yes aGVHD n=5.

Probability of a) relapse b) event free (EFS) and c) overall survival (OS) in ALL patients from all risk categories who had pre-HCT flow MRD measured and lived to day +55 after transplant (n=105). Patients listed as MRD+ had ≥ 0.1% measured by flow cytometry in BM within 2 weeks initiating their preparative regimen. Patients listed as experiencing aGVHD had onset of any grade of aGVHD before day +55. MRD <0.1% and no aGVHD n=51, MRD <0.1% and yes aGVHD n=37, MRD ≥0.1% and no aGVHD n=12, MRD ≥0.1% and yes aGVHD n=5.